Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MaxiVAX
Geneva, Switzerlandmaxivax.ch ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MaxiVAX's lead program demonstrated safety in over 30 patients during Phase I. A multi-center, open-label Phase II trial was initiated in head and neck cancers. The approach uses autologous tumor cells combined with encapsulated GM-CSF-secreting cells to stimulate broad anti-tumor immunity. IND approval was obtained for chordoma trials.
- Therapeutic areas
- Oncology
- Modalities
- VaccineCell therapyBiologic
- Industry
- Biotech
02
Partnerships
Minaris Regenerative Medicine (manufacturing/CDMO partnership)Scailyte (data-driven clinical collaboration)
Beyond the preview
Go deeper on MaxiVAX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MaxiVAX.